M Pharmaceutical Appoints Kulick as Development Adviser

M Pharmaceutical Inc. (CSE:MQ) announced it has engaged Dr. Roy M. Kulick, MD, as clinical development adviser. Dr. Kulick will prepare clinical trial plans for the company’s lead product, Trimeo, which are capsules for the treatment of obesity.
Dr. Kulick is an MBA-trained physician with a record of success in clinical research, life sciences start-ups and regulatory strategy. After receiving his MD from the University of Pennsylvania School of Medicine, Dr. Kulick has served in a number of academic and industry roles including division director at Cincinnati Children’s Hospital; executive director of Schuman Associates IRB; senior scientist at the Proctor & Gamble Co., where he led clinical evaluation of weight management technologies; and director of clinical research at Ethicon Endo-Surgery (a Johnson & Johnson Company). Currently, Dr. Kulick is an entrepreneur-in-residence at the University of Cincinnati technology accelerator for commercialization and at the University of Louisville Coulter translational partnership as well as the principal of ConneXion Life Sciences.
M Pharmaceutical CEO, Matthew Lehman, stated:

I am pleased that Dr. Kulick has agreed to join M Pharmaceutical at this crucial time as we plan for the clinical development of Trimeo, I believe his clinical development experience will prove beneficial to our growth plans.

Connect with M Pharmaceutical Inc. (CSE:MQ) to receive an Investor Kit